BIOMAT Database Logo BIOMAT Database Logo

Resistance to 1-[(2-hydroxyethoxy)methyl]-6-(phenylthio)thymine derivatives is generated by mutations at multiple sites in the HIV-1 reverse transcriptase. 1995

R W Buckheit, and V Fliakas-Boltz, and S Yeagy-Bargo, and O Weislow, and D L Mayers, and P L Boyer, and S H Hughes, and B C Pan, and S H Chu, and J P Bader
Virology Research Group, Southern Research Institute, Frederick Research Center, Maryland 21701, USA.

Virus isolates resistant to 1-[(2-hydroxyethoxy)methyl]-6-(phenylthio)thymine (HEPT) and a highly potent HEPT derivative, [1-benzyloxymethyl-5-ethyl-6-(alpha-pyridylthio)uracil] (NSC 648400, E-BPTU), were selected in cell culture. Cross-resistance evaluation indicated that the two drug-resistant virus isolates were phenotypically distinct from one another although each of the virus isolates was resistant to both of the HEPT derivatives. The virus isolate resistant to NSC 648400 had a single amino acid change in the reverse transcriptase (Y181C) which resulted in cross-resistance to all of the nonnucleoside reverse transcriptase inhibitors evaluated, with the exception of calanolide A. The NSC 648400-resistant virus isolate exhibited 15-fold enhanced sensitivity to calanolide A. The virus isolate selected in the presence of HEPT exhibited a single amino acid change (P236L) which was not cross-resistant to other nonnucleoside RT inhibitors tested with the exception of the two HEPT derivatives. This HEPT-resistant virus isolate exhibited enhanced sensitivity (5- to 10-fold) to thiazolobenzimidazole. We have used both virus isolates with defined single amino acid changes in the RT and bacterially expressed RTs with site-directed amino acid substitutions to test the effects of a wide variety of mutations on the activity of NSC 648400. Single mutations at amino acids 101, 103, 106, 181, or 236 yielded virus with high resistance (> 20-fold) to NSC 648400, while lower levels of resistance were seen with mutations at amino acids 98, 100, or 108. These results suggest that several changes in the conformation of the nonnucleoside inhibitor binding site of the HIV-1 reverse transcriptase can affect the inhibitory activity of the HEPT class of compounds.

UI MeSH Term Description Entries
D011725 Pyridines Compounds with a six membered aromatic ring containing NITROGEN. The saturated version is PIPERIDINES.
D011994 Recombinant Proteins Proteins prepared by recombinant DNA technology. Biosynthetic Protein,Biosynthetic Proteins,DNA Recombinant Proteins,Recombinant Protein,Proteins, Biosynthetic,Proteins, Recombinant DNA,DNA Proteins, Recombinant,Protein, Biosynthetic,Protein, Recombinant,Proteins, DNA Recombinant,Proteins, Recombinant,Recombinant DNA Proteins,Recombinant Proteins, DNA
D002460 Cell Line Established cell cultures that have the potential to propagate indefinitely. Cell Lines,Line, Cell,Lines, Cell
D004305 Dose-Response Relationship, Drug The relationship between the dose of an administered drug and the response of the organism to the drug. Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response
D004352 Drug Resistance, Microbial The ability of microorganisms, especially bacteria, to resist or to become tolerant to chemotherapeutic agents, antimicrobial agents, or antibiotics. This resistance may be acquired through gene mutation or foreign DNA in transmissible plasmids (R FACTORS). Antibiotic Resistance,Antibiotic Resistance, Microbial,Antimicrobial Resistance, Drug,Antimicrobial Drug Resistance,Antimicrobial Drug Resistances,Antimicrobial Resistances, Drug,Drug Antimicrobial Resistance,Drug Antimicrobial Resistances,Drug Resistances, Microbial,Resistance, Antibiotic,Resistance, Drug Antimicrobial,Resistances, Drug Antimicrobial
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000998 Antiviral Agents Agents used in the prophylaxis or therapy of VIRUS DISEASES. Some of the ways they may act include preventing viral replication by inhibiting viral DNA polymerase; binding to specific cell-surface receptors and inhibiting viral penetration or uncoating; inhibiting viral protein synthesis; or blocking late stages of virus assembly. Antiviral,Antiviral Agent,Antiviral Drug,Antivirals,Antiviral Drugs,Agent, Antiviral,Agents, Antiviral,Drug, Antiviral,Drugs, Antiviral
D012194 RNA-Directed DNA Polymerase An enzyme that synthesizes DNA on an RNA template. It is encoded by the pol gene of retroviruses and by certain retrovirus-like elements. EC 2.7.7.49. DNA Polymerase, RNA-Directed,RNA-Dependent DNA Polymerase,Reverse Transcriptase,RNA Transcriptase,Revertase,DNA Polymerase, RNA Directed,DNA Polymerase, RNA-Dependent,RNA Dependent DNA Polymerase,RNA Directed DNA Polymerase
D013329 Structure-Activity Relationship The relationship between the chemical structure of a compound and its biological or pharmacological activity. Compounds are often classed together because they have structural characteristics in common including shape, size, stereochemical arrangement, and distribution of functional groups. Relationship, Structure-Activity,Relationships, Structure-Activity,Structure Activity Relationship,Structure-Activity Relationships
D013941 Thymine One of four constituent bases of DNA. 5-Methyluracil,5 Methyluracil

Related Publications

R W Buckheit, and V Fliakas-Boltz, and S Yeagy-Bargo, and O Weislow, and D L Mayers, and P L Boyer, and S H Hughes, and B C Pan, and S H Chu, and J P Bader
Conformational study of the HIV-1 reverse transcriptase inhibitor 1-[(2-hydroxyethoxy)methyl]-6-(phenylthio)thymine (HEPT).
February 1999, Biological chemistry,
R W Buckheit, and V Fliakas-Boltz, and S Yeagy-Bargo, and O Weislow, and D L Mayers, and P L Boyer, and S H Hughes, and B C Pan, and S H Chu, and J P Bader
Structure-Based design of [(2-Hydroxyethoxy)methyl]-6-(phenylthio)-thymine derivatives as nonnucleoside HIV-1 reverse transcriptase Inhibitors: From HEPTs to Sulfinyl-substituted HEPTs.
September 2022, Bioorganic chemistry,
R W Buckheit, and V Fliakas-Boltz, and S Yeagy-Bargo, and O Weislow, and D L Mayers, and P L Boyer, and S H Hughes, and B C Pan, and S H Chu, and J P Bader
Human immunodeficiency virus type 1 drug-resistance patterns with different 1-[(2-hydroxyethoxy)methyl]-6-(phenylthio)thymine derivatives.
October 1993, Molecular pharmacology,
R W Buckheit, and V Fliakas-Boltz, and S Yeagy-Bargo, and O Weislow, and D L Mayers, and P L Boyer, and S H Hughes, and B C Pan, and S H Chu, and J P Bader
A novel lead for specific anti-HIV-1 agents: 1-[(2-hydroxyethoxy)methyl]-6-(phenylthio)thymine.
December 1989, Journal of medicinal chemistry,
R W Buckheit, and V Fliakas-Boltz, and S Yeagy-Bargo, and O Weislow, and D L Mayers, and P L Boyer, and S H Hughes, and B C Pan, and S H Chu, and J P Bader
Thorough evaluation of OECD principles in modelling of 1-[(2-hydroxyethoxy)methyl]-6-(phenylthio)thymine derivatives using QSARINS.
October 2020, SAR and QSAR in environmental research,
R W Buckheit, and V Fliakas-Boltz, and S Yeagy-Bargo, and O Weislow, and D L Mayers, and P L Boyer, and S H Hughes, and B C Pan, and S H Chu, and J P Bader
Synthesis and potent anti-HIV-1 activity of novel 6-benzyluracil analogues of 1-[(2-hydroxyethoxy)methyl]-6-(phenylthio)thymine.
June 1996, Journal of medicinal chemistry,
R W Buckheit, and V Fliakas-Boltz, and S Yeagy-Bargo, and O Weislow, and D L Mayers, and P L Boyer, and S H Hughes, and B C Pan, and S H Chu, and J P Bader
Differential activities of 1-[(2-hydroxyethoxy)methyl]-6-(phenylthio)thymine derivatives against different human immunodeficiency virus type 1 mutant strains.
April 1995, Antimicrobial agents and chemotherapy,
R W Buckheit, and V Fliakas-Boltz, and S Yeagy-Bargo, and O Weislow, and D L Mayers, and P L Boyer, and S H Hughes, and B C Pan, and S H Chu, and J P Bader
Common features in the interaction of tetrahydroimidazo[4,5,1-jk][1,4]benzodiazepin-2(1H)-one and -thione and 1-[(2-hydroxyethoxy)methyl]-6-(phenylthio)thymine derivatives with the human immunodeficiency virus type 1 reverse transcriptase.
May 1992, Molecular pharmacology,
R W Buckheit, and V Fliakas-Boltz, and S Yeagy-Bargo, and O Weislow, and D L Mayers, and P L Boyer, and S H Hughes, and B C Pan, and S H Chu, and J P Bader
Synthesis and anti-HIV activity of 2-, 3-, and 4-substituted analogues of 1-[(2-hydroxyethoxy)methyl]-6-(phenylthio)thymine (HEPT).
April 1991, Journal of medicinal chemistry,
R W Buckheit, and V Fliakas-Boltz, and S Yeagy-Bargo, and O Weislow, and D L Mayers, and P L Boyer, and S H Hughes, and B C Pan, and S H Chu, and J P Bader
A new class of HIV-1-specific 6-substituted acyclouridine derivatives: synthesis and anti-HIV-1 activity of 5- or 6-substituted analogues of 1-[(2-hydroxyethoxy)methyl]-6-(phenylthio)thymine (HEPT).
January 1991, Journal of medicinal chemistry,
Copied contents to your clipboard!